These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15474016)

  • 21. Transcriptional regulation of the human TRIF (TIR domain-containing adaptor protein inducing interferon beta) gene.
    Hardy MP; McGGettrick AF; O'Neill LA
    Biochem J; 2004 May; 380(Pt 1):83-93. PubMed ID: 14960149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.
    Yamamoto M; Sato S; Hemmi H; Hoshino K; Kaisho T; Sanjo H; Takeuchi O; Sugiyama M; Okabe M; Takeda K; Akira S
    Science; 2003 Aug; 301(5633):640-3. PubMed ID: 12855817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TLR3/TRIF signalling pathway regulates IL-32 and IFN-β secretion through activation of RIP-1 and TRAF in the human cornea.
    Park GB; Hur DY; Kim YS; Lee HK; Yang JW; Kim D
    J Cell Mol Med; 2015 May; 19(5):1042-54. PubMed ID: 25754842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling.
    Matsumoto M; Kikkawa S; Kohase M; Miyake K; Seya T
    Biochem Biophys Res Commun; 2002 May; 293(5):1364-9. PubMed ID: 12054664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4.
    Doyle SE; O'Connell R; Vaidya SA; Chow EK; Yee K; Cheng G
    J Immunol; 2003 Apr; 170(7):3565-71. PubMed ID: 12646618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oligomerized TICAM-1 (TRIF) in the cytoplasm recruits nuclear BS69 to enhance NF-kappaB activation and type I IFN induction.
    Takaki H; Oshiumi H; Sasai M; Kawanishi T; Matsumoto M; Seya T
    Eur J Immunol; 2009 Dec; 39(12):3469-76. PubMed ID: 19795416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-beta induction through toll-like receptor 3 depends on double-stranded RNA structure.
    Okahira S; Nishikawa F; Nishikawa S; Akazawa T; Seya T; Matsumoto M
    DNA Cell Biol; 2005 Oct; 24(10):614-23. PubMed ID: 16225392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TRIF-mediated TLR3 and TLR4 signaling is negatively regulated by ADAM15.
    Ahmed S; Maratha A; Butt AQ; Shevlin E; Miggin SM
    J Immunol; 2013 Mar; 190(5):2217-28. PubMed ID: 23365087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction.
    Oshiumi H; Matsumoto M; Funami K; Akazawa T; Seya T
    Nat Immunol; 2003 Feb; 4(2):161-7. PubMed ID: 12539043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29.
    Sirén J; Pirhonen J; Julkunen I; Matikainen S
    J Immunol; 2005 Feb; 174(4):1932-7. PubMed ID: 15699120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors.
    DiPerna G; Stack J; Bowie AG; Boyd A; Kotwal G; Zhang Z; Arvikar S; Latz E; Fitzgerald KA; Marshall WL
    J Biol Chem; 2004 Aug; 279(35):36570-8. PubMed ID: 15215253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein.
    O'Reilly SM; Moynagh PN
    Biochem Biophys Res Commun; 2003 Apr; 303(2):586-93. PubMed ID: 12659860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation.
    Meylan E; Burns K; Hofmann K; Blancheteau V; Martinon F; Kelliher M; Tschopp J
    Nat Immunol; 2004 May; 5(5):503-7. PubMed ID: 15064760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2.
    Van Huffel S; Delaei F; Heyninck K; De Valck D; Beyaert R
    J Biol Chem; 2001 Aug; 276(32):30216-23. PubMed ID: 11390377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6.
    Heyninck K; Beyaert R
    FEBS Lett; 1999 Jan; 442(2-3):147-50. PubMed ID: 9928991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutting Edge: NF-kappaB-activating kinase-associated protein 1 participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN regulatory factor 3 activation.
    Sasai M; Oshiumi H; Matsumoto M; Inoue N; Fujita F; Nakanishi M; Seya T
    J Immunol; 2005 Jan; 174(1):27-30. PubMed ID: 15611223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NAK-associated protein 1 participates in both the TLR3 and the cytoplasmic pathways in type I IFN induction.
    Sasai M; Shingai M; Funami K; Yoneyama M; Fujita T; Matsumoto M; Seya T
    J Immunol; 2006 Dec; 177(12):8676-83. PubMed ID: 17142768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes.
    Li K; Chen Z; Kato N; Gale M; Lemon SM
    J Biol Chem; 2005 Apr; 280(17):16739-47. PubMed ID: 15737993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto's autoimmune thyroiditis.
    Harii N; Lewis CJ; Vasko V; McCall K; Benavides-Peralta U; Sun X; Ringel MD; Saji M; Giuliani C; Napolitano G; Goetz DJ; Kohn LD
    Mol Endocrinol; 2005 May; 19(5):1231-50. PubMed ID: 15661832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An inhibitory effect of A20 on NF-kappaB activation in airway epithelium upon influenza virus infection.
    Onose A; Hashimoto S; Hayashi S; Maruoka S; Kumasawa F; Mizumura K; Jibiki I; Matsumoto K; Gon Y; Kobayashi T; Takahashi N; Shibata Y; Abiko Y; Shibata T; Shimizu K; Horie T
    Eur J Pharmacol; 2006 Jul; 541(3):198-204. PubMed ID: 16765340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.